A Phase II, Multi-centre Open Label Study to Assess the Efficacy and Safety of Oral Apabetalone With Background Dapagliflozin in Subjects With Long -COVID-19 (Post-COVID-19 Conditions) and Type 2 Diabetes Mellitus (T2DM)

This is an open label, multicentre, phase II clinical trial that aims to assess the efficacy and safety of oral Apabetalone with background dapagliflozin for up to 12 weeks in T2DM patients with a history of probable or confirmed SARS-CoV-2 infection, with symptoms within 3 months from the onset of COVID-19 that last for at least 2 months and cannot be explained by an alternative diagnosis.

Start Date15 Apr 2025

Sponsor / Collaborator

Resverlogix Corp.

NCT03160430

/ Not yet recruitingPhase 1/2

A Two-Part Phase 2a Study in Patients With End-Stage Renal Disease Treated With Hemodialysis; Part A is an Open-Label Study Arm to Evaluate the Effect of Hemodialysis on the Pharmacokinetics of 100 mg RVX000222; and Part B is a Double-Blind, Randomized, Placebo-Controlled, Sequential Cross-Over Study Arm to Evaluate the Efficacy, Safety, and Pharmacokinetics of RVX000222

This is a multi-center, two-part study; Part A and Part B. Part A of the study is an open-label, single-dose pharmacokinetic (PK) evaluation of 100 mg RVX000222 on dialysis and non-dialysis days in eight (8) End Stage Renal Disease (ESRD) patients who receive hemodialysis as standard of care.
Part B of the study is a double-blind, placebo-controlled study in up to thirty six (36) ESRD patients receiving hemodialysis using a sequential cross-over design with RVX000222 at a daily oral dose of 100 mg b.i.d. (200 mg per day) or matching placebo in combination with SoC.
The primary objective of the study is to evaluate if treatment with RVX000222 in combination with standard of care (SoC) decreases plasma alkaline phosphatase in comparison to placebo and SoC.

Start Date22 Nov 2024

Sponsor / Collaborator

Resverlogix Corp.

NCT04915300

/ Unknown statusPhase 2IIT

Apabetalone for Pulmonary Arterial Hypertension: a Phase 2 Clinical Study

Throughout the past twenty years, numerous specific pharmacologic agents targeting the endothelial dysfunction associated with PAH have emerged. Short term placebo-controlled randomized trials assessing PAH-specific monotherapy with these molecules have reported improvements in pulmonary hemodynamics and exercise capacity. A recent meta-analysis also documented a reduction in short-term mortality of about ≈40% with such therapies. Several randomized clinical trials evaluating PAH-specific combination therapy have been conducted. Our recent meta-analysis showed that combination therapy was associated with a 35% risk reduction for the occurrence of clinical worsening compared to monotherapy. Nonetheless, the investigators also showed 17% of PAH patients receiving combination therapy still experienced clinical worsening over a median exposure of 16 weeks. Moreover, long-term survival on PAH-specific also therapy remains poor in the modern era, with a yearly mortality rate of 15 % in incident idiopathic PAH. The identification of innovative therapeutic targets and validation of these complementary therapeutic interventions are thus urgently needed in PAH.
The investigators and others (K. Stenmark, University of Colorado and H. Bogaard, VU University Medical Center, Amsterdam, personal communications), have published strong evidence that BRD4 plays a key role in the pathological phenotype in PAH accounting for disease progression and showed that BRD4 inhibition can reverse PAH in several animal models. Intriguingly, coronary artery disease (CAD) and metabolic syndrome are more prevalent in PAH compared with the global population, suggesting a link between these diseases. Interestingly, BRD4 is also a trigger for calcification and remodeling processes and regulates transcription of lipoprotein and inflammatory factors, all of which are important in PAH and CAD. Apabetalone, an orally available BRD4 inhibitor, is now in a clinical development stage with a good safety profile.
The overall objective of the study is to explore the efficacy and safety of apabetalone as an add-on therapy for adult PAH patients and to inform the conduct and the design of a Phase 3 trial.
The primary objective of the study is to assess the efficacy of apabetalone as evaluated by the change in PVR over a period of 24 weeks compared to placebo in adult subjects with PAH on stable background therapy.
Secondary objectives include changes at week 24 in 6MWD, plasma NT-proBNP concentration, WHO functional class, ESC/ERS risk stratification score, health-related quality of life and additional hemodynamic data from right heart.
Exploratory objectives are to evaluate the effects of apabetalone compared to placebo in adult subjects with PAH on mortality and clinically relevant morbidity events, and on circulating levels and transcription changes in whole blood markers of metabolism, vascular calcification, inflammation, DNA damage and leucocyte expression of BMPR2.

Start Date01 Oct 2023

Sponsor / Collaborator

Université Laval

[+2]

100 Clinical Results associated with Apabetalone

100 Translational Medicine associated with Apabetalone

100 Patents (Medical) associated with Apabetalone

108

Literatures (Medical) associated with Apabetalone

01 Feb 2026·Advanced Science

Brd4 BD1 Domain Antagonism of MS436 Preserves Blood‐Brain Barrier Integrity via Rnf43/β‐Catenin Signaling Pathway

Article

Author: Yong Zhang ; Yushan Du ; Xiaochen Zhang ; Fen Ji ; Jingjing Zhang ; Chenxiao Li ; Jiangwei Xia ; Jianwei Jiao ; Shuang Liu ; Shukui Zhang ; Sihan Li

Abstract:

Blood‐brain barrier (BBB) disruption is central to neurodegenerative and cerebrovascular diseases, but its causal role and therapeutic targeting remain challenging. Bromodomain and extraterminal domain (BET) proteins, particularly Brd4, regulate transcription via dual bromodomains (BD1, BD2). While BD1 antagonists are explored for tumors and BD2 antagonists for inflammation, their impact on cerebrovascular integrity is unclear. Crucially, opposing BBB effects of domain‐specific BET antagonism: the BD2 antagonist RVX208 disrupt the BBB, whereas the BD1 antagonist MS436 significantly reduces leakage and improves neurological outcomes, revealing therapeutic potential is demonstrated. Mechanistically, endothelial Brd4 critically suppresses BBB stability. Its ablation upregulates tight junction (TJ) proteins. Brd4, acting exclusively through its BD1 domain, destabilizes TJs via Rnf43 is identified, which promotes β‐catenin and TJ protein degradation. This defines a novel Brd4 BD1/Rnf43/β‐catenin axis essential for BBB integrity. The findings establish Brd4 BD1 inhibition as a novel BBB‐protective strategy and position MS436 for repurposing in cerebrovascular diseases, necessitating reevaluation of domain‐specific BET targeting for neurovascular pathologies.

01 Dec 2025·DRUG DISCOVERY TODAY

Inhibition of bromodomain and extra-terminal motif (BET) proteins in pediatric sarcoma: A systematic review of in vitro and in vivo studies

Review

Author: Lambona, Chiara ; Rota, Rossella ; Locatelli, Franco ; Zwergel, Clemens ; Marchese, Cinzia ; Cassandri, Matteo ; Macrì, Elisa ; Barillari, Giovanni ; Ferraro, Erika ; Pomella, Silvia

BET inhibitors (BETi), especially those targeting BRD4, show promising preclinical activity against pediatric sarcomas by disrupting oncogenic transcription. This systematic review of 26 studies highlights the anti-proliferative and pro-apoptotic effects of BETi across five pediatric sarcoma types. In vivo data show a decrease in tumor growth, with better results when combined with other therapies. This systematic review revealed that, whereas early investigations mostly rely on pan-BETi, recent studies focus on newer and more specific agents. Accordingly, we reported that ABBV-744 and RVX-208, which selectively target the BD2 domain, and GNE-987, a specific BRD4 degrader, are the most promising inhibitors. However, ABBV-075, a pan-BETi, also exhibits high efficacy, being effective at low doses. Nevertheless, translating these experimental findings into clinical practice remains difficult because of resistance, toxicity, and inconsistent responses. Future approaches include using biomarkers for patient selection, developing isoform-specific BETi, and designing rational combination therapies to enhance treatment for these aggressive pediatric cancers.

01 May 2025·Kidney International Reports

Corrigendum to “The Bromodomain and Extraterminal Protein Inhibitor Apabetalone Ameliorates Kidney Injury in Diabetes by Regulating Cholesterol Accumulation and Modulating the Gut Microbiota” [Volume 10, Issue 2, February 2025, Pages 522-534]

Author: Qiuling Fan ; Xin Li ; Min Wang ; He Sun ; Zhaohui Huang ; Yonghong Zhu

[This corrects the article DOI: 10.1016/j.ekir.2024.11.022.].

News (Medical) associated with Apabetalone

18 Feb 2026

·www.resverlogix.com

Resverlogix Closes $2.8 Million Shares-for-Interest Private Placement

CALGARY, Alberta, February 18, 2026, Resverlogix Corp. (“Resverlogix”) (TSX:RVX) announced today that it has closed a $2.8 million shares-for-interest private placement with an immediate family member (the “Subscriber”) of Resverlogix’s Chairman and CEO. Under the terms of the shares-for-interest transaction, the Subscriber subscribed for 28,000,000 common shares at CAD$0.10 per share for aggregate proceeds of CAD$2.8 million. After giving effect to the transaction, the Subscriber holds approximately 9.7% of Resverlogix's common shares. The common shares are subject to a four-month hold period. The shares-for-interest transaction followed the settlement of CAD$2.8 million of accrued interest on indebtedness owing to the Subscriber by Zenith Capital Corp. (“Zenith”) by way of the assignment to the Subscriber of an equal amount of accrued interest on indebtedness owing by Resverlogix to Zenith Capital Corp. The securities described herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws, and accordingly, may not be offered or sold to, or for the account or benefit of, persons in the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act), except in compliance with the registration requirements of the U.S. Securities Act and applicable state securities requirements or pursuant to exemptions therefrom. This press release does not constitute an offer to sell or a solicitation of an offer to buy any of Resverlogix's securities to, or for the account or benefit of, persons in the United States or U.S. Persons. Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company’s clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix common shares trade on the Toronto Stock Exchange (TSX:RVX). Follow us on: X.com: @Resverlogix_RVX LinkedIn: https://www.linkedin.com/company/resverlogix-corp-/ This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts”, and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 www.resverlogix.com

28 May 2024

·www.biospace.com

Resverlogix Announces Updated Annual and Special Meeting of Shareholders

Calgary, Alberta--(News - May 28, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") announced today that its Annual and Special Meeting of Shareholders (the "Meeting") will be held on Wednesday, July 31, 2024, commencing at approximately 1:00 pm (MT), as opposed to as previously scheduled for June 27, 2024. A Notice of Meeting and Management Information Circular, containing the matters to be considered at the Meeting, will be delivered to shareholders and filed on SEDAR+ at . Following the formal business of the Meeting, a corporate update presentation will be provided. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: Forward-Looking Statements: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the upcoming Annual and Special Meeting of Shareholders and the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR+ at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: To view the source version of this press release, please visit

22 Feb 2024

·www.biospace.com

Resverlogix Announces Change to Its Board of Directors.

Calgary, Alberta--(News - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's President and CEO. About Resverlogix Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients' lives by restoring biological functions - altered by serious illnesses such as cardiovascular disease - back to a healthier state. The Company's clinical program is focused on evaluating the lead epigenetic candidate apabetalone for the treatment of cardiovascular disease, associated comorbidities, and post COVID-19 conditions. Resverlogix has partnered with EVERSANA™, the pioneer of next generation commercial services to the global life sciences industry, to support the rapid commercialization of apabetalone for cardiovascular disease, post COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States. Resverlogix common shares trade on the Toronto Stock Exchange (TSX: RVX). Follow us on: Twitter: @Resverlogix_RVX LinkedIn: For further information please contact: Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252 Or visit our website: This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts", and other similar expressions. In particular, this news release includes forward looking information related to the potential role of apabetalone in the treatment of patients with cardiovascular disease, post COVID-19 conditions, pulmonary arterial hypertension, associated comorbidities, and other chronic diseases. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at . The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. To view the source version of this press release, please visit

Executive Change

100 Deals associated with Apabetalone

External Link

KEGG	Wiki	ATC	Drug Bank
D11131	Apabetalone	-	DB12000

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Post Acute COVID 19 Syndrome	Phase 3	Jordan	Resverlogix Corp.	15 Apr 2025
Post Acute COVID 19 Syndrome	Phase 3	Saudi Arabia	Resverlogix Corp.	15 Apr 2025
Post Acute COVID 19 Syndrome	Phase 3	United Arab Emirates	Resverlogix Corp.	15 Apr 2025
COVID-19	Phase 3	Canada	Resverlogix Corp.	14 Jan 2022
Coronary Disease	Phase 3	-	Resverlogix Corp.	08 Dec 2015
Angina Pectoris	Phase 3	Croatia	Resverlogix Corp.	01 Nov 2015
Angina Pectoris	Phase 3	Germany	Resverlogix Corp.	01 Nov 2015
Angina Pectoris	Phase 3	Netherlands	Resverlogix Corp.	01 Nov 2015
Angina Pectoris	Phase 3	Poland	Resverlogix Corp.	01 Nov 2015
Angina Pectoris	Phase 3	Slovakia	Resverlogix Corp.	01 Nov 2015

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02586155 (BETonMACE, ERA2023)	Phase 3	Chronic Kidney Diseases	-	Apabetalone 100 mg	xgjsvclbma(dnnjkvryfe): HR = 0.5 (95% CI, 0.26 - 0.96), P-Value = 0.04	Positive	14 Jun 2023
				Placebo
NCT02586155 (BETonMACE, ASN2021)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	-	Apabetalone 1-25 µ M	xvrsriyyaf(fmhiccuope) = zajixtohxh kxcvcstqtv (xynrykesfp ) View more	Positive	27 Oct 2021
NCT03655704 (APPRoAcH-p, GlobeNewswire) Manual	Phase 1	Pulmonary Arterial Hypertension	7	Apabetalone	mutudviaqj(mcibqvebvk) = improved hlbgavejzm (noknwyqzjz )	Positive	08 Sep 2021
NCT02586155 (BETonMACE, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	2,425	Atorvastatin+Rosuvastatin+Apabetalone (High-Intensity Statin Therapy+RVX000222)	lxkoxnewtl = rnhlwnochr oyzzlsylno (fhosohqkys, dupwjncxet - tyqndrbwpd) View more	-	20 Aug 2021
				Placebo+Atorvastatin+Rosuvastatin (High-Intensity Statin Therapy+Placebo)	lxkoxnewtl = vptupfainv oyzzlsylno (fhosohqkys, fpprhfwhle - lstkcrydvg) View more
NCT02586155 (BETonMACE, ERA2021)	Phase 3	Chronic Kidney Diseases	-	APABETALONE (TGF-β1)	oounddgezq(kxwronkgnz) = sarvlxhduu oflebzkwns (zocptqleqt ) View more	Positive	29 May 2021
				APABETALONE (LPS)	sjfneoqfbh(gifnorlevb) = wghrcnjgak qqfzrzxsdh (oghzxprwgf )
NCT02586155 (BETonMACE, ASN2020)	Phase 3	Diabetes Mellitus, Type 2 \| Angina Pectoris \| Coronary Artery Disease ... View more	2,425	Apabetalone	ejemplofzp(kdmhioplsx) = afhanxjzlo blmfhabpol (njsiqswthw, 1.67 - 3.44) View more	Positive	19 Oct 2020
				Placebo	ejemplofzp(kdmhioplsx) = ofohniybgw blmfhabpol (njsiqswthw, 1.67 - 3.44) View more
NCT02586155 (BETonMACE, ERA2020)	Phase 3	Diabetes Mellitus, Type 2 \| Acute Coronary Syndrome \| Chronic Kidney Diseases	2,425	Apabetalone (ABP)	ostwisemdg(ldondzqloa) = otqbauwbmd cyguqhvrbf (oimlalbjar )	Positive	06 Jun 2020
				Placebo (PBO)	ostwisemdg(ldondzqloa) = qjvejokolg cyguqhvrbf (oimlalbjar )
NCT02586155 (BETonMACE, Pubmed \| J Coll Physicians Surg Pak \| JAMA) Manual	Phase 2	Diabetes Mellitus, Type 2 \| Acute Coronary Syndrome	2,425	Apabetalone	npzlvuaitk(jwklwhnjay) = zxyhwtanxs vcwwhqjaht (urfujebbrt ) View more	Negative	28 Apr 2020
				Placebo	npzlvuaitk(jwklwhnjay) = ftrytfezce vcwwhqjaht (urfujebbrt ) View more
BETonMACE (ASN2019)	Phase 3	Acute Coronary Syndrome \| Diabetes Mellitus Alkaline Phosphatase	2,425	Apabetalone	fhkomqxadq(vojshojjxf) = skzumnfbud vgujidvszg (dtkonmvdtz )	Positive	05 Nov 2019
NCT02586155 (BETonMACE, Pubmed \| Am Heart J)	Phase 3	Acute Coronary Syndrome \| Diabetes Mellitus	2,425	Apabetalone 100 mg	cljypqhwcn(mmdmvlhbnl) = wzrivbemgr yuoeitwcxm (firdeyohec )	-	01 Nov 2019

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis